Key result
Metformin is linked to ~65% lower CHD risk in T2DM, while higher HbA1c predicts risk.
Why the study?
Coronary heart disease is a prevalent complication of type 2 diabetes mellitus, but few studies have investigated the coronary imaging characteristics and risk factors in this population.
What are the coronary imaging characteristics and risk factors for coronary heart disease in patients with type 2 diabetes mellitus?
Case-Control (n=103)
What are the coronary imaging characteristics and risk factors for coronary heart disease in patients with type 2 diabetes mellitus?
Odds Ratio: 1.472 (95% CI 1.234–1.755)
p-value: p=0.000
Higher fasting blood glucose and HbA1c are independent risk factors for coronary heart disease in patients with type 2 diabetes, while metformin treatment is associated with a protective effect.
May support risk stratification in T2DM; leaves open need for prospective validation before practice change.
BACKGROUND Coronary heart disease (CHD) is a prevalent type 2 diabetes mellitus (T2DM) complication. Further, the risk stratification before angiography may help diagnose T2DM with CHD early. However, few studies have investigated the coronary imaging characteristics and risk factors of patients with T2DM complicated with CHD. AIM To compare the differences in coronary imaging between patients with T2DM with and without CHD, determine the risk factors of T2DM complicated with CHD, and establish a predictive tool for diagnosing CHD in T2DM. METHODS This study retrospectively analyzed 103 patients with T2DM from January 2022 to May 2024. They are categorized based on CHD occurrence into: (1) The control group, consisting of patients with T2DM without CHD; and (2) The observation group, which includes patients with T2MD with CHD. Age, sex, smoking and drinking history, CHD family history, metformin (MET) treatment pre-admission, body mass index, fasting blood glucose (FBG), triglyceride (TG), total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), serum creatinine, blood urea nitrogen (BUN), alanine aminotransferase, aspartate aminotransferase, glycosylated hemoglobin (HbA1c), and coronary imaging data of both groups were collected from the medical record system. Logistic risk analysis was conducted to screen risk factors. The prediction model’s prediction efficiency was evaluated with receiver operating characteristic curves. RESULTS The control and observation groups consisted of 48 and 55 cases, respectively. The two groups were statistically different in terms of age (t = 2.006, P = 0.048), FBG (t = 6.038, P = 0.000), TG (t = 2.015, P = 0.047), LDL-C (t = 2.017, P = 0.046), and BUN (t = 2.035, P = 0.044). The observation group demonstrated lower proportions of patients receiving MET (χ 2 = 5.073, P = 0.024) and higher proportions of patients with HbA1c of > 7.0% (χ 2 = 6.980, P = 0.008) than the control group. The observation group consisted of 15, 17, and 23 cases of moderate stenosis, severe stenosis, and occlusion, respectively, with a greater number of coronary artery occlusion cases than the control group (χ 2 = 6.399, P = 0.041). The observation group consisted significantly higher number of diffuse lesion cases at 35 compared with the control group (χ 2 = 15.420, P = 0.000). The observation group demonstrated a higher right coronary artery (RCA) stenosis index (t = 6.730, P = 0.000), circumflex coronary artery (LCX) stenosis index (t = 5.738, P = 0.000), and total stenosis index (t = 7.049, P = 0.000) than the control group. FBG [odds ratio (OR) = 1.472; 95% confidence interval (CI): 1.234-1.755; P = 0.000] and HbA1c (OR = 3.197; 95%CI: 1.149-8.896; P = 0.026) were independent risk factors for T2DM complicated with CHD, whereas MET (OR = 0.350; 95%CI: 0.129-0.952; P = 0.040) was considered a protective factor for CHD in T2DM. CONCLUSION Coronary artery occlusion is a prevalent complication in patients with T2DM. Patients with T2MD with CHD demonstrated a higher degree of RCA and LCX stenosis than those with T2DM without CHD. FBG, HbA1c, and MET treatment history are risk factors for T2DM complicated with CHD.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2025) conducted a case-control in Type 2 diabetes mellitus with coronary heart disease (n=103). Fasting blood glucose, HbA1c, and Metformin treatment vs. Patients without coronary heart disease was evaluated on Coronary heart disease complication (OR 1.472, 95% CI 1.234-1.755, p=0.000). Fasting blood glucose (OR 1.472; 95% CI 1.234-1.755) and HbA1c (OR 3.197; 95% CI 1.149-8.896) were independent risk factors for CHD in T2DM, whereas metformin (OR 0.350) was a protective factor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: